



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/624,670	07/24/2000	Pradip Mukerji	6407.US.p2	7619

7596

06/18/2002

Steven F Weinstock
Abbott Laboratories
D-377/AP6D-2
100 Abbott Park Road
Abbott Park, IL 60064-6050

EXAMINER

RAO, MANJUNATH N

ART UNIT

PAPER NUMBER

1652

DATE MAILED: 06/18/2002

10

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/624,670

Applicant(s)

MUKERJI ET AL.

Examiner

Manjunath N Rao

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 11 January 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 1-49 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) 1-49 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ 6) ☐ Other: _____

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-5, 8-24, 26-28 47-48, drawn to polynucleotides, vectors and host cells and method of making a polypeptide, classified in class 435, subclass 69.1.
- II. Claims 6-7, 49, drawn to a polypeptide, classified in class 435, subclass 232.
- III. Claim 25, drawn to one or more plant oils or acids, classified in class 426, subclass 601+.
- IV. Claims 29-34, drawn to a method of producing PUFA, classified in class 435, subclass 134.
- V. Claims 35-39, drawn to a nutritional composition comprising a PUFA, classified in class 435, subclass 232.
- VI. Claim 40, drawn to a pharmaceutical composition comprising a PUFA, classified in class 435, subclass 232.
- VII. Claims 41-44, drawn to an animal feed comprising a PUFA, classified in class 426, subclass 635.
- VIII. Claim 45, drawn to a cosmetic comprising a PUFA, classified in class 514, subclass 844.
- IX. Claim 46, drawn to a method of preventing or treating a condition, classified in class 424, subclass 94.1.

The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1652

Inventions I, II, III, V-VIII are patentably distinct from each other. The polynucleotide of group I, the polypeptide of group II, the plant oil of group III and PUFA of groups V-VIII each comprise amino acid sequences and nucleotide sequences and fatty acid sequences which are chemically unrelated, do not require each other for practice; have separate utilities, such as use of the group I polypeptide to PUFA elongation reaction versus the use of polynucleotide in a hybridization reaction versus the use of the plant oil as an aromatic compound versus the use of nutritional composition to nourish humans versus the use of pharmaceutical composition in treatment of certain disorders, versus the use of animal feed to feed and nourish the health of animals versus the use of cosmetic to enhance beauty and are subject to separate manufacture and sale. The groups have acquired separate status in the art and separate fields of search.

Inventions I, II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polynucleotides can be used as probes in a hybridization reaction and the polypeptide can be used to raise specific antibodies as opposed to its use in the method of group IV.

Inventions III and IV are patentably distinct from each other. The inventions of groups III is a product which is neither made nor used in the method of group IV. The groups have

Art Unit: 1652

acquired separate status in the art and separate fields of search as further evidenced by their separate classification.

Inventions IV and V-VIII are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the PUFA of groups V-VIII can be chemically synthesized as opposed to the enzymatic method of group IV.

Inventions V and IX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the nutritional composition can be used to enhance the health of normal individuals as opposed to the method of treatment of group IX.

Inventions I-IV, VI-VIII and invention IX are patentably distinct from each other. The products of groups I-IV, VI-VIII are neither used nor made in the method of group IX. . The groups have acquired separate status in the art and separate fields of search as further evidenced by their separate classification.

Art Unit: 1652

Inventions IV and IX are patentably distinct from each other. The method of producing PUFA of group IV and the method of treating an individual of group IX are unrelated as they comprise distinct steps, utilize different products and produce different results. The groups have acquired separate status in the art and separate fields of search as further evidenced by their separate classification.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manjunath N Rao whose telephone number is 703-306-5681. The examiner can normally be reached on 7.30 a.m. to 4.00 p.m..


Application/Control Number: 09/624,670

Page 6

Art Unit: 1652

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-306-0196.


Manjunath N. Rao
June 4, 2002